DARZALEX Faspro 1800 mg / 30,000 UNT in 15 mL Injection
RxNorm 2375141

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2375141 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: DARZALEX Faspro 1800 mg / 30,000 UNT in 15 mL Injection.

The following semantic concepts and normalized strings are associated with this clinical entity:

SBD
15 mL daratumumab-fihj 120 mg/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
AUI:12408032
View
SY
DARZALEX Faspro (daratumumab-hyaluronidase-fihj 1800 mg /30,000 UNT) per 15 mL Injection
AUI:12408041
View
PSN
DARZALEX Faspro 1800 mg / 30,000 UNT in 15 mL Injection
AUI:12408033
View
SY
DARZALEX Faspro 1800 mg / 30,000 UNT per 15 mL Injection
AUI:12408034
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDPrescribable

Semantic Branded Drug (SBD):
15 mL daratumumab-fihj 120 mg/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
(Atom ID: 12408032)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
15 ML daratumumab-fihj 120 MG/ML / hyaluronidase-fihj 2000 UNT/ML Injection [Darzalex Faspro]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2375141
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12408032
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBD
Semantic Branded Drug (Ingredient + Strength + Dose Form + Brand Name)
Source Code
2375141
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN AI
{2375131} 1721947
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AI
{2375133} 5464
RXCUI of BOSS Active Ingredient preceded by RXCUI of SCDC responsible for value
RXN AM
{2375131} 1721947
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AM
{2375133} 5464
RXCUI of BOSS Active Moiety preceded by RXCUI of SCDC responsible for value
RXN AVAILABLE STRENGTH
120 MG/ML (expressed as daratumumab-fihj) / 2000 UNT/ML (expressed as hyaluronidase-fihj)
Available drug strengths listed in the order of ingredients from the drug
RXN BOSS FROM
{2375131} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN BOSS FROM
{2375133} AI
Source of BOSS as either from the active ingredient (AI) or the active moiety (AM) preceded by RXCUI of SCDC responsible for value
RXN HUMAN DRUG
US
Drug available for use in Humans
RXN QUANTITY
15 ML
Normal Form quantity factor
SYPrescribable

Synonym (SY):
DARZALEX Faspro (daratumumab-hyaluronidase-fihj 1800 mg /30,000 UNT) per 15 mL Injection
(Atom ID: 12408041)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
DARZALEX Faspro (daratumumab-hyaluronidase-fihj 1800 MG /30,000 UNT) per 15 ML Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2375141
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12408041
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2375141
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
PSNPrescribable

Prescribable Name (PSN):
DARZALEX Faspro 1800 mg / 30,000 UNT in 15 mL Injection
(Atom ID: 12408033)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
DARZALEX Faspro 1800 MG / 30,000 UNT in 15 mL Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2375141
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12408033
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2375141
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
DARZALEX Faspro 1800 mg / 30,000 UNT per 15 mL Injection
(Atom ID: 12408034)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
DARZALEX Faspro 1800 MG / 30,000 UNT per 15 mL Injection
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2375141
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12408034
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2375141
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Daratumumab and Hyaluronidase-fihj Injection


Daratumumab and hyaluronidase-fihj injection is used with other medications to treat multiple myeloma (a type of cancer of the bone marrow) in newly diagnosed adults who are unable to receive certain other treatments. Daratumumab and hyaluronidase-fihj injection is also used in combination with other medications to treat multiple myeloma in adults that has returned or has not improved after other treatment(s). This medication is also used alone to treat adults with multiple myeloma who have received at least three lines of treatment with other medications and were not treated successfully. Daratumumab is in a class of medications called monoclonal antibodies. It works by helping the body to slow or stop the growth of cancer cells. Hyaluronidase-fihj is an endoglycosidase. It helps to keep daratumumab in the body longer so that the medication will have a greater effect.
[Learn More]


* Please review the disclaimer below.